Advanced Filters
noise

Hemophilia Clinical Trials

A listing of Hemophilia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 95 clinical trials
D Darintr Sosothikul, Diplomate

Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration To study pharmacokinetic, side effect of low dose Emicizumab

3 - 30 years of age Male Phase 2/3
K Kathelijn Fischer, Dr, MD

Pharmacokinetic-guided Dosing of Emicizumab

The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.

1 years of age Male Phase 4
S Shuo Chen

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

To evaluate the time of response, sustained remission rate and relapse rate of CD38 monoclonal antibody (Daratumumab) combined corticosteroid in the treatment of AHA. To evaluate the safety of CD38 monoclonal antibody in the treatment of AHA.

18 years of age All Phase 4
F Fabiane P Farias, PT

Embolization in Hereditary Coagulopathies

This is a longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and/or ankles followed up at the Centro de Hemofilia HCFMUSP, after approval by the ethics and research committee. They will undergo imaging tests (X-rays and …

years of age All Phase N/A
L Lijun Liu

Safety and Tolerability of VGB-R04 in Patients With Haemophilia B

An Open-Label, Non-Randomized, uncontrolled, single-dose pilot study of VGB-R04 in subjects with Hemophilia B.

18 - 75 years of age Male Phase N/A
S Site contact

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

This is a Phase 1, open- label, non- randomized, uncontrolled, single dose pilot study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of BBM-H901 in hemophilia B subjects with ≤2IU/dl residual FIX levels and aged 12-18 years old. BBM-H901 is an adeno-associated viral (AAV) vector designed …

12 - 18 years of age Male Phase 1
S Shuo Chen, MD

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

A non-randomized, open-label study to evaluate the safety, kinetics and efficacy of a single intravenous infusion of ZS801 in hemophilia B subjects with endogenous FIX ≤2%.

18 - 65 years of age Male Phase N/A
Y Yun-Shan Jian

Individualized Exercise Combined With Manual Therapy in Severe Hemophilia Patients With Polyarthropathy

The aim of this study is to investigate the effect of individualized physical therapy, combined manual therapy and exercise intervention, for pain perception, range of motion (ROM), muscle strength, joint health, cardiopulmonary endurance and quality of life (QoL) in patients with severe hemophilia A and multiple hemophilic arthropathy.

20 years of age All Phase N/A
S Shuo Chen, MD

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

A non-randomized, open-label, dose-escalation, phase I/II study to evaluate the safety, tolerability, kinetics and efficacy of a single intravenous infusion of ZS801 in hemophilia B subjects with endogenous FIX ≤2%.

18 years of age Male Phase 1/2
M Mariia V Smagina

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-002 in subjects with hemophilia В. The study will have a dose-escalation design with elements of phase I/II seamless adaptive design.

18 years of age Male Phase 1/2

Simplify language using AI